Publications in 2016
247. Myers JB, Stoffel JT, Welk B, Elliott S. TAU focused issue on adult management of neurogenic bladder. Transl Androl Urol 2016;5(1):1-2.
248. Husmann DA. Long-term complications following bladder augmentations in patients with spina bifida: bladder calculi, perforation of the augmented bladder and upper tract deterioration. Transl Androl Urol 2016;5(1):3-11.
249. Powell CR. Not all neurogenic bladders are the same: a proposal for a new neurogenic bladder classification system. Transl Androl Urol 2016;5(1):12-21.
250. Clark R, Welk B. Patient reported outcome measures in neurogenic bladder. Transl Androl Urol 2016;5(1):22-30.
251. Allio BA, Peterson AC. Urodynamic and physiologic patterns associated with the common causes of neurogenic bladder in adults. Transl Androl Urol 2016;5(1):31-38.
252. Loftus CJ, Wood HM. Congenital causes of neurogenic bladder and the transition to adult care. Transl Androl Urol 2016;5(1):39-50.
253. Cameron AP. Medical management of neurogenic bladder with oral therapy. Transl Androl Urol 2016;5(1):51-62.
254. Weckx F, Tutolo M, De Ridder D, Van der Aa F. The role of botulinum toxin A in treating neurogenic bladder. Transl Androl Urol 2016;5(1):63-71.
255. Vigil HR, Hickling DR. Urinary tract infection in the neurogenic bladder. Transl Androl Urol 2016;5(1):72-87.
256. Shridharani AN, Brant WO. The treatment of erectile dysfunction in patients with neurogenic disease. Transl Androl Urol 2016;5(1):88-101.
257. Trofimenko V, Hotaling JM. Fertility treatment in spinal cord injury and other neurologic disease. Transl Androl Urol 2016;5(1):102-116.
258. Sanford MT, Suskind AM. Neuromodulation in neurogenic bladder. Transl Androl Urol 2016;5(1):117-126.
259. Stoffel JT. Detrusor sphincter dyssynergia: a review of physiology, diagnosis, and treatment strategies. Transl Androl Urol 2016;5(1):127-135.
260. Levy ME, Elliott SP. Reconstructive techniques for creation of catheterizable channels: tunneled and nipple valve channels.Transl Androl Urol 2016;5(1):136-144.
261. Myers JB, Mayer EN, Lenherr S; for the Neurogenic Bladder Research Group (NBRG.org). Management options for sphincteric deficiency in adults with neurogenic bladder. Transl Androl Urol 2016;5(1):145-157.
262. Gao LM. Professor Wayne J.G. Hellstrom: incidence of Peyronie’s disease. Transl Androl Urol 2016;5(1):158-159.
263. Gao LM, Seliman HX. Doctor Chris G. McMahon: epidemiology and diagnosis of ejaculatory dysfunction. Transl Androl Urol 2016;5(1):160-161.
264. Welliver C, Köhler TS, McVary KT. Preface on current topics in men’s health. Transl Androl Urol 2016;5(2):166
265. Lin G, Zhang H, Sun F, Lu Z, Reed-Maldonado A, Lee YC, Wang G, Banie L, Lue TF. Brain-derived neurotrophic factor promotes nerve regeneration by activating the JAK/STAT pathway in Schwann cells. Transl Androl Urol 2016;5(2):167-175.
266. Lowe G. Optimizing outcomes in vasectomy: how to ensure sterility and prevent complications. Transl Androl Urol 2016;5(2):176-180.
267. Smith-Harrison L, Patel A, Smith RP. The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction. Transl Androl Urol 2016;5(2):181-186.
268. Hehemann MC, Kashanian JA. Can lifestyle modification affect men’s erectile function? Transl Androl Urol 2016;5(2):187-194.
269. Chiles KA. Hypogonadism and erectile dysfunction as harbingers of systemic disease. Transl Androl Urol 2016;5(2):195-200.
270. Parker A, Bruha M, Akinola O, Welliver C. A summary of the controversy surrounding off-label medications in men’s health.Transl Androl Urol 2016;5(2):201-206.
271. Desroches B, Kohn TP, Welliver C, Pastuszak AW. Testosterone therapy in the new era of Food and Drug Administration oversight. Transl Androl Urol 2016;5(2):207-212.
272. Pan MM, Kovac JR. Beyond testosterone cypionate: evidence behind the use of nandrolone in male health and wellness.Transl Androl Urol 2016;5(2):213-219.
273. Schaive C, Kohler TS. An inside perspective on anabolic steroid abuse. Transl Androl Urol 2016;5(2):220-224.
274. Garcia MM. Men’s health and transgender surgery: a urologist’s perspective. Transl Androl Urol 2016;5(2):225-227.
275. Reed-Maldonado AB, Lue TF. A syndrome of erectile dysfunction in young men? Transl Androl Urol 2016;5(2):228-234.
276. Rot I, Wassersug RJ, Walker LM. What do urologists think patients need to know when starting on androgen deprivation therapy? The perspective from Canada versus countries with lower gross domestic product. Transl Androl Urol 2016;5(2):235-247.
277. Majzoub A, Arafa M, Al-Said S, Dabbous Z, Aboulsoud S, Khalafalla K, Elbardisi H. Premature ejaculation in type II diabetes mellitus patients: association with glycemic control. Transl Androl Urol 2016;5(2):248-254.
278. Xin Z, Lin G, Lei H, Lue TF, Guo Y. Clinical applications of low-intensity pulsed ultrasound and its potential role in urology.Transl Androl Urol 2016;5(2):255-266.
279. Ramsay S, Ringuette-Goulet C, Langlois A, Bolduc S. Clinical challenges in tissue-engineered urethral reconstruction.Transl Androl Urol 2016;5(2):267-270.
280. Seiler R. Predicting response to neoadjuvant chemotherapy in bladder cancer: controversies remain with genomic DNA sequencing. Transl Androl Urol 2016;5(2):271-273.
281. Zhou S. Professor Viraj A. Master: surgery is a single “strike”. Transl Androl Urol 2016;5(2):274-275.
282. Xu EX. Dr. Richard Santucci: developments in trauma and reconstructive urology. Transl Androl Urol 2016;5(2):276-277.
283. Hellstrom WJ. Current state of affairs of Peyronie’s disease. Transl Androl Urol 2016;5(3):278-279.
284. Al-Thakafi S, Al-Hathal N. Peyronie’s disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up. Transl Androl Urol 2016;5(3):280-289
285. Terrier JE, Nelson CJ. Psychological aspects of Peyronie’s disease. Transl Androl Urol 2016;5(3):290-295.
286. Barrett-Harlow B, Wang R. Oral therapy for Peyronie’s disease, does it work? Transl Androl Urol 2016;5(3):296-302.
287. Usta MF, Ipekci T. Penile traction therapy for Peyronie’s disease—what’s the evidence? Transl Androl Urol 2016;5(3):303-309.
288. Chong W, Tan RB. Injectable therapy for Peyronie’s disease. Transl Androl Urol 2016;5(3):310-317.
289. Chen R, McCraw C, Lewis R. Plication procedures—excisional and incisional corporoplasty and imbrication for Peyronie’s disease. Transl Androl Urol 2016;5(3):318-333.
290. Hatzichristodoulou G. Grafting techniques for Peyronie’s disease. Transl Androl Urol 2016;5(3):334-341.
291. Anaissie J, Yafi FA. A review of surgical strategies for penile prosthesis implantation in patients with Peyronie’s disease.Transl Androl Urol 2016;5(3):342-350.
292. Gaffney CD, Pagano MJ, Weinberg AC, Small AC, Kuehas FE, Egydio PH, Valenzuela RJ. Lengthening strategies for Peyronie’s disease. Transl Androl Urol 2016;5(3):351-362.
293. Sangkum P. Research highlights on stem cell therapy for the treatment of Peyronie’s disease. Transl Androl Urol 2016;5(3):363-365.
294. Chung E. Pro: does shockwave therapy have a place in the treatment of Peyronie’s disease? Transl Androl Urol 2016;5(3):366-370.
295. Alkhayal A, Carrier S. Con: does shockwave therapy have a place in the treatment of Peyronie’s disease? Transl Androl Urol 2016;5(3):371-374.
296. Chi T, Usawachintachit M, Filippou P, Bayne D, Hu W, Chang H, Xia L, Chen Q, Xue W, He H, Long Q, Arsovska O, Taylor E, Paterson R, Sur RL, Chew B, Stoller ML, Li J. Significant differences in struvite and cystine stone frequency seen among Chinese nephrolithiasis patients living in North America compared to those living in China. Transl Androl Urol 2016;5(3):375-380.
297. Zhang WR, Garrett GL, Arron ST, Garcia MM. Laser hair removal for genital gender affirming surgery. Transl Androl Urol 2016;5(3):381-387.
298. Elhilali MM, Elkoushy MA. Greenlight laser vaporization versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: evidence from randomized controlled studies. Transl Androl Urol 2016;5(3):388-392.
299. Leone A, Diorio G, Zargar-Shoshtari K, Spiess PE. Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy. Transl Androl Urol 2016;5(3):393-395.
300. Regauer S. Mast cell activation syndrome in pain syndromes bladder pain syndrome/interstitial cystitis and vulvodynia. Transl Androl Urol 2016;5(3):396-397.
301. Xu EX. Professor Jay Simhan: surgery improves the quality of life for patients. Transl Androl Urol 2016;5(3):399-400.
302. McMahon CG. Ejaculatory dysfunction. Transl Androl Urol 2016;5(4):401.
303. McMahon CG. Ejaculatory dysfunction—the evolution of a new understanding. Transl Androl Urol 2016;5(4):402-408.
304. Saitz TR, Serefoglu EC. The epidemiology of premature ejaculation. Transl Androl Urol 2016;5(4):409-415.
305. Parnham A, Serefoglu EC. Classification and definition of premature ejaculation. Transl Androl Urol 2016;5(4):416-423.
306. Waldinger MD. The pathophysiology of lifelong premature ejaculation. Transl Androl Urol 2016;5(4):424-433.
307. McMahon CG, Jannini EA, Serefoglu EC, Hellstrom WJ. The pathophysiology of acquired premature ejaculation. Transl Androl Urol 2016;5(4):434-449.
308. DeLay KJ, Nutt M, McVary KT. Ejaculatory dysfunction in the treatment of lower urinary tract symptoms. Transl Androl Urol 2016;5(4):450-459.
309. Abdo CH. The impact of ejaculatory dysfunction upon the sufferer and his partner. Transl Androl Urol 2016;5(4):460-469.
310. Althof SE. Patient reported outcomes in the assessment of premature ejaculation. Transl Androl Urol 2016;5(4):470-474.
311. Althof SE. Psychosexual therapy for premature ejaculation. Transl Androl Urol 2016;5(4):475-481.
312. Hisasue Si. The drug treatment of premature ejaculation. Transl Androl Urol 2016;5(4):482-486.
313. McMahon CG. Emerging and investigational drugs for premature ejaculation. Transl Androl Urol 2016;5(4):487-501.
314. Moon DG. Is there a place for surgical treatment of premature ejaculation? Transl Androl Urol 2016;5(4):502-507.
315. McMahon CG. The design and methodology of premature ejaculation interventional studies. Transl Androl Urol 2016;5(4):508-525.
316. Jiann BP. The office management of ejaculatory disorders. Transl Androl Urol 2016;5(4):526-540.
317. Di Sante S, Mollaioli D, Gravina GL, Ciocca G, Limoncin E, Carosa E, Lenzi A, Jannini EA. Epidemiology of delayed ejaculation. Transl Androl Urol 2016;5(4):541-548.
318. Chen J. The pathophysiology of delayed ejaculation. Transl Androl Urol 2016;5(4):549-562.
319. Perelman MA. Psychosexual therapy for delayed ejaculation based on the Sexual Tipping Point model. Transl Androl Urol 2016;5(4):563-575.
320. Abdel-Hamid IA, Elsaied MA, Mostafa T. The drug treatment of delayed ejaculation. Transl Androl Urol 2016;5(4):576-591.
321. Parnham A, Serefoglu EC. Retrograde ejaculation, painful ejaculation and hematospermia. Transl Androl Urol 2016;5(4):592-601.
322. Waldinger MD. Post orgasmic illness syndrome (POIS). Transl Androl Urol 2016;5(4):602-606.
323. Anaissie J, Yafi FA, Hellstrom WJ. Surgery is not indicated for the treatment of premature ejaculation. Transl Androl Urol 2016;5(4):607-612.
324. Lavien G, Zaid U, Peterson AC. Commentary on genitourinary cancer survivorship: physical activity and prostate cancer survivorship. Transl Androl Urol 2016;5(4):613-615.
325. Ornstein MC, Garcia JA, Sharifi N. Screening for functional kinases in metastatic prostate cancer: a glimmer of hope for kinase inhibition. Transl Androl Urol 2016;5(4):616-619.
326. Xu EX. Professor Larry I. Lipshultz: genetic research in male infertility. Transl Androl Urol 2016;5(4):620-621.
327. Xu EX. Prof. Eric A. Klein: genomic research in prostate cancer. Transl Androl Urol 2016;5(4):622-623.
328. Gao S. Prof. Allen Seftel: be part of new innovations. Transl Androl Urol 2016;5(4):624-625.
329. Gao S. Dr. Jeffrey Tomaszewski: the application of prostate cancer genomic tests. Transl Androl Urol 2016;5(4):626-627.
330. Gao LM. Dr. Ryan P. Smith: management of chronic orchialgia. Transl Androl Urol 2016;5(4):628-629.
331. Gao LM. Prof. Rajeev Kumar: adrenal masses. Transl Androl Urol 2016;5(4):630-631.